Vaidheesh Annaswamy is a successful senior business leader from the most admired Fortune 100 companies with more than 35 years of diverse experience in the healthcare and FMCG Industry, including at Johnson and Johnson, Pfizer and GSK. He has proven expertise in general management with a strong background in market creation and leadership development. Further, he has rich experience in building strong leadership for brands/franchises across varied categories (healthcare and FMCG) and in multi-grid and multi-cultural Locations in the Asia-Pacific region.

Jane holds a BSc in Pharmacology and a PhD in Toxicology from the University of London and recently completed an MBA in International Health Care Management. As a board member at the Institute of Clinical Research, she helps shape its strategic direction and promote clinical research careers. With over 35 years of experience in oncology drug development, including executive leadership and project management, she now focuses on driving strategic innovation in oncology and collaborating with pharma and biotech companies to enhance drug development.

Dr Laura Brown is Course Director of the MSc in Clinical Research, University of Cardiff and a Training and QA Consultant. Dr Brown has held a number of international and senior management positions in the pharmaceutical industry. She has worked for several international companies including GlaxoWellcome, Hoechst Marion Roussel and Phoenix International. She was a member of the Editorial board of the Good Clinical Practice Journal for 10 years. She is author of several books including Project Management for the Pharmaceutical Industry, a Practical Guide to the Clinical Trial Directive and several articles on the new EU Clinical Trial Regulation.

What makes Norstella's AI different?
The differentiator is the breadth of the underlying pharmaceutical dataset. Norstella can connect information from across the pipeline-to-patient journey, creating insights that would be difficult to generate from isolated datasets. AI extends the value that can be derived from that information.

What can pharma teams do now that was not possible two years ago?
One major advance is the ability to understand how patients appear in real-world healthcare and translate this into more effective targeting. AI can help bridge the gap between the controlled environment of a clinical trial and the much less structured reality of patient treatment.

How can AI accelerate the journey from pipeline to patient?
Trial design, portfolio investment and market access decisions all consume substantial time. AI can help organisations make these decisions using a broader evidence base and do so more quickly, supporting faster development and potentially wider access to successful therapies.

Jones is chairman of the Oxford-based AI drug discovery company e-Therapeutics and a member of the board of the USA vaccine company Techimmune LLC. He was formerly R&D Director of the Wellcome Foundation, a director of Allergan Inc. and Director General of the Association of the British pharmaceutical industry (ABPI ). He is a visiting professor at Kings College London.

Viren is the founder and managing member of Mehta Partners, LLC, where his analytical insights on global healthcare have shaped biopharmaceutical strategies and investments. With over 30 years of experience and degrees from the University of Southern California and UCLA, he has worked closely with BioPharma leaders and investment managers. His recent initiative, Gather Health, aims to enhance patient outcomes by connecting patients with their healthcare providers and personal networks. Viren also contributes to philanthropy through the Viram Foundation and has a background in strategic planning with Merck & Co., Wood MacKenzie, and S.G. Warburg.

His experience extends across sales and marketing as well as country management of an international life science corporation. His current focus is in competency development of people through education, both formal and informal. Phornvit also sits on committees of national bodies in education and business. His academic background is in economics and business administration.

Peter Pitts is a Visiting Professor at the University of Paris Medical School and President of the Center for Medicine in the Public Interest. He previously served as an Associate Commissioner of the US FDA and is active with the Council for International Organizations of Medical Sciences (CIOMS) to enhance patient involvement in medicine development. Pitts has authored numerous publications in top journals like The Lancet and Nature Biotechnology, and holds editorial roles with various medical and regulatory science publications. He is based in New York City.

Smith began his career in research and development with ICI and SmithKline Beecham, and later transitioned to commercial roles at SB Pharmaceuticals, focusing on global brand management. After earning a PhD in Molecular Biology and an MBA, he moved into asset management and venture capital with 3i Group, managing several life science funds and winning the Techmark technology fund manager of the year award in 2007. He subsequently worked as director of business development and head of corporate finance at PharmaVentures, and taught life science valuation at the University of Cambridge. In 2017, Smith joined ICON's Pricing & Market Access group, advising on product valuation and commercialization, and later returned to work at Edison.

Dr. Spiegel has over 30 years of extensive R&D and operational experience in biopharmaceuticals including Big Pharma, biotech, and academic startups as well as advisory roles with venture capital and private equity. Dr Spiegel was Director of the Developmental Therapeutics Program at NYU Medical Center and then spent over 25 years at Schering-Plough where he joined as the first Director for Oncology Clinical Research. He subsequently held a series of senior executive positions, including Senior Vice President for worldwide Clinical Research and Chief Medical Officer. During his time at Schering-Plough he took numerous drug candidates through clinical development and was involved with over 30 NDA approvals. Since 2011 Dr. Spiegel has been a consultant to the biotech industry and has served on the Scientific Advisory Board and Board of Directors of multiple biotech companies. He is currently the president of Spiegel Consulting LLC and an Assistant Professor of Medicine at Weill Cornell Medical College. He is also a Senior Advisor to the private equity firm Warburg Pincus and an Advisor to the Israel Biotech Fund. Dr. Spiegel received his B.A. from Yale University and his M.D. from the University of Pennsylvania. He completed his specialty training at the National Cancer Institute, National Institutes of Health (NIH).

Dr Brian Tempest has held many Non-Executive roles in the Corporate, Educational and NGO Sectors. These positions include Pharmaceuticals, Hospital Management, Medical Diagnostics, Packaging, Financial Services, University Advisory Boards and the United Nations Patent Pool. He is currently Non-Executive Chairman of Touch Medical Media Group Holdings in the UK and is on the Board of a number of international Healthcare Companies as well as advising others from Europe and Asia.

Brian has previously worked for GSK, Pfizer, Sanofi and Sun Pharmaceuticals in leadership positions. He holds FRSC, FRSM, BSc, PhD and DSc qualifications and now resides in Wales, UK.

Mike Ward is a highly regarded, award-winning writer, editor, commentator and thought leadership leader with more than four decades of experience covering the global life sciences and healthcare industries. Throughout his career, he has held senior editorial and content leadership positions at several of the industry's most influential organisations, including BioCentury, Informa and Clarivate.

Widely recognised for his ability to translate complex scientific, commercial and policy developments into compelling business intelligence, Mike has written extensively on drug discovery, clinical development, healthcare innovation, regulatory change and pharmaceutical strategy. He is a sought-after moderator, interviewer and speaker, having led discussions with industry executives, scientists, investors and policymakers across the global life sciences ecosystem.

Over the course of his career, Mike has built a reputation as one of the sector's most respected voices, combining deep industry knowledge with a talent for identifying emerging trends and helping organisations understand their strategic implications. His work has informed senior decision-makers across the pharmaceutical, biotechnology, investment and healthcare communities.